Overexpression of UHRF1 is significantly associated with poor prognosis in laryngeal squamous cell carcinoma

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  Pi, Jing Ting ^a   Lin, Ye ^a   Quan, Qiu ^a   Chen, Li Li ^a   Jiang, Li Zhu ^a   Chi, Wang ^b   Chen, Hong Yan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathological parameters; Immunohistochemistry; Laryngeal squamous cell carcinoma; Prognosis; UHRF1

Indexed keywords

BINDING PROTEIN; MESSENGER RNA; UBIQUITIN LIKE WITH PHD AND RING FINGER DOMAIN 1; UNCLASSIFIED DRUG; CCAAT ENHANCER BINDING PROTEIN; TUMOR MARKER; UHRF1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; SQUAMOUS CELL CARCINOMA; AGED; BIOSYNTHESIS; DISEASE COURSE; GENETICS; LARYNX TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CCAAT-ENHANCER-BINDING PROTEINS; DISEASE PROGRESSION; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84891840500     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0613-9     Document Type: Article

References (23)

1. Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin North Am. 2008;41:673-95, v. (Pubitemid 351836078)
2. Du LS, Mao WM, Chen WQ, Zhang SW, Yu CD, Zheng RS, Xiang QM, Wang XH. Incidence and mortality of larynx cancer in china during 2003-2007. Chinese J Epidemiol. 2012;33:395-8.
3. Jenkins Y, Markovtsov V, Lang W, et al. Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell. 2005;16:5621-9. (Pubitemid 41752212)
4. Bronner C, Achour M, Arima Y, Chataigneau T, Saya H, Schini-Kerth VB. The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future. Pharmacol Ther. 2007;115:419-34. (Pubitemid 47362377)
5. Hopfner R, Mousli M, Jeltsch JM, et al. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Res. 2000;60:121-8. (Pubitemid 30058741)
6. Arima Y, Hirota T, Bronner C, et al. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells. 2004;9:131-42. (Pubitemid 38312957)
7. Jeanblanc M, Mousli M, Hopfner R, et al. The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. Oncogene. 2005;24:7337-45. (Pubitemid 41622238)
8. Unoki M, Nishidate T, Nakamura Y. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene. 2004;23:7601-10. (Pubitemid 39424918)
9. Unoki M, Daigo Y, Koinuma J, Tsuchiya E, Hamamoto R, Nakamura Y. UHRF1 is a novel diagnostic marker of lung cancer. Br J Cancer. 2010;103:217-22.
10. Unoki M, Kelly JD, Neal DE, Ponder BA, Nakamura Y, Hamamoto R. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer. 2009;101:98-105.
11. Wang F, Yang YZ, Shi CZ, et al. UHRF1 promotes cell growth and metastasis through repression of p16(ink(4)a) in colorectal cancer. Ann Surg Oncol. 2012;19:2753-62. doi: 10.1245/s10434-011-2194-1.
12. Pita JM, Banito A, Cavaco BM, Leite V. Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer. 2009;101:1782-91.
13. Babbio F, Pistore C, Curti L, et al. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression. Oncogene. 2012;31:4878-87.
14. Jin W, Chen L, Chen Y, et al. UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer. Breast Cancer Res Treat. 2010;123:359-73. doi: 10.1007/s10549-009-0652-2.
15. Lorenzato M, Caudroy S, Bronner C, et al. Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions. Hum Pathol. 2005;36:1101-7. (Pubitemid 41443262)
16. Yang GL, Zhang LH, Bo JJ, et al. UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer. Med Oncol. 2012;29:842-7. doi: 10.1007/s12032-011-9983-z.
17. Bostick M, Kim JK, Esteve PO, Clark A, Pradhan S, Jacobsen SE. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science. 2007;317:1760-4. (Pubitemid 47461842)
18. Bronner C, Fuhrmann G, Chedin FL, Macaluso M, Dhe-Paganon S. UHRF1 links the histone code and DNA methylation to ensure faithful epigenetic memory inheritance. Genet Epigenet. 2010;2009:29-36.
19. Daskalos A, Oleksiewicz U, Filia A, et al. UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer. Cancer. 2011;117:1027-37.
20. Avvakumov GV, Walker JR, Xue S, et al. Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature. 2008;455:822-5.
21. Sharif J, Muto M, Takebayashi S, et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature. 2007;450:908-12. (Pubitemid 350231331)
22. Hopfner R, Mousli M, Oudet P, Bronner C. Overexpression of ICBP90, a novel CCAAT-binding protein, overcomes cell contact inhibition by forcing topoisomerase II alpha expression. Anticancer Res. 2002;22:3165-70. (Pubitemid 36070088)
23. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology. 2005;129:1454-63. (Pubitemid 41597388)